SAN FRANCISCO, Jan 13 (Reuters) - AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use of artificial intelligence to accelerate the discovery of new drugs.
The companies did not disclose financial terms. In a press release, Modella AI said its "foundation models" and AI agents would be integrated into oncology research and development to support clinical development and biomarker discovery.
"Oncology drug development is becoming more complex, more data-rich and more time-sensitive," said Gabi Raia, Modella AI's chief commercial officer, adding that joining AstraZeneca would allow it to deploy its tools in global trials and clinical settings.
AstraZeneca said that this was the first acquisition of an AI firm by a big pharmaceutical company.
In an interview at the JP Morgan Healthcare Conference, AstraZeneca Chief Financial Officer Aradhana Sarin said the acquisition would "supercharge" the company's quantitative pathology and biomarker discovery efforts by bringing more data and AI capabilities in-house.
The deal was one of a number of pacts between major drug firms and AI companies that were unveiled at the healthcare conference, including a $1 billion collaboration between Nvidia and Eli Lilly. They plan to build a new research lab using Nvidia's latest-generation AI chips.
Modella will accelerate AstraZeneca’s efforts to make pathology more quantitative - using computers to analyze biopsies for relevant proteins and correlate them with clinical data - so AstraZeneca can develop “highly targeted biomarkers and then highly targeted therapeutics,” Sarin said.
The deal is an expansion of a multi-year collaboration that the companies unveiled in July.
Sarin said that partnership served as a "test drive," adding that AstraZeneca ultimately wanted Modella's data, foundation models and AI talent in-house.
She said AI tools could be used to more rapidly select patients for drug trials, which could increase the odds of clinical success and cut related costs.
(Reporting by Maggie Fick; Editing by Thomas Derpinghaus)
latest_posts
- 1
Manual for Tracking down Spending plan Agreeable Travel Objections - 2Hamas Navy head, engineer of Khan Yunis tunnel network killed in Gaza, IDF confirms
- 3In these U.S. groups, deaths now exceed births. What’s happening?
- 4Oldest evidence of human fire-making discovered at site in England
- 5The most effective method to Execute a Lung-Solid Eating routine After a Cellular breakdown in the lungs Finding
- Kids get diseases like lupus, too. As researchers hunt better treatments, this camp brings joy
- AI’s errors may be impossible to eliminate – what that means for its use in health care
- See the famous winged horse Pegasus fly in the autumn night sky
- 'Heated Rivalry' is just the tip of the iceberg. How hockey became the sexiest sport
- 4 astronauts are en route home from ISS after medical issue forces early exit
- Jury says Johnson & Johnson owes $40 million to 2 cancer patients who used talcum powders
- 5 Family SUVs for 2024: Which One Accommodates Your Family's Needs\uff1f
- Israeli archaeologists launch project to trace origins of ancient pottery
- The Significance of Prenuptial Arrangements in Separation Procedures
